DIAGNOS Welcomes Founder of National Vision Associates, Ed Weiner, to its Advisory Board for the United States

written by Raj Shah | June 10, 2025

June 10, 2025 (Source) – Diagnos Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (*AI*), is thrilled to announce that Mr. Ed Weiner has joined the Corporation's Advisory Board.

Mr. Weiner will team up with Dr. Tomas J. Philipson, former vice chairman and acting chairman of the White House Council of Economic Advisers, to provide valuable insights to DIAGNOS about the US optical market. Mr. Weiner is a seasoned entrepreneur and has been a leader in the optical industry for decades. He was the first to introduce Ralph Lauren Eyewear. He also partnered with Walmart to open 400 optical locations within Walmart's chain of stores. Mr. Weiner was also chairman and founder of National Vision Associates, one of the largest optical retailers in the USA.

"We are honored to welcome Ed to our Advisory Board," said André Larente, President and CEO of DIAGNOS. "In our opinion, his deep knowledge of the US optical market will contribute to bring DIAGNOS as one of the main AI driven healthcare solutions among opticians and optometrists across the US."

Mr. Larente added, "DIAGNOS has built an AI platform to analyze retina images, these images are taken by thousands of

optometrists worldwide. According to recent VisionWatch data, the US saw approximately 111 million routine eye exams and 60 million medical eye exams in 2020. DIAGNOS, along with its partners can address this growing market". DIAGNOS recently opened its US office in south Florida to support its US prospects and clients.

About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical eye-related health problems. By leveraging Artificial Intelligence, DIAGNOS aims to provide more information to healthcare clinicians to enhance diagnostic accuracy, streamline workflows, and improve patient outcomes on a global scale.

Additional information is available at www.diagnos.com and www.sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.